目的了解医院产房自将乙肝疫苗(Hepatitis B Vaccine,HepB)纳入免疫规划后新生儿首针乙肝疫苗的接种情况及探讨其影响因素,为新生儿首针乙肝疫苗预防接种提供科学依据。方法采取回顾性调查分析方法,对2006～2009年鹿寨县所有医院产房出...目的了解医院产房自将乙肝疫苗(Hepatitis B Vaccine,HepB)纳入免疫规划后新生儿首针乙肝疫苗的接种情况及探讨其影响因素,为新生儿首针乙肝疫苗预防接种提供科学依据。方法采取回顾性调查分析方法,对2006～2009年鹿寨县所有医院产房出生新生儿首针乙肝疫苗接种情况进行调查分析。结果医院产房新生儿首针乙肝疫苗的接种率99.96%,及时接种率93.84%,影响未及时接种的因素以"早产、低体重、新生儿窒息、胎儿窘迫、新生儿疾病"为主,非疾病因素以"产程延长、胎膜早破、过期妊娠、羊水过少、婴儿吐奶、监护人拒接种等"为主。结论医务人员严格履行告知义务和提高新生儿疾病筛查、诊治力度,有利于及时接种首针乙肝疫苗。展开更多
Objective： The aim of our study was to investigate the early outcome of the taxotere and cisplatin chemora- diotherapy to the advanced cervical cancer. Methods： Fifty-six cases with cervical cancer （FIGO lib to IVa...Objective： The aim of our study was to investigate the early outcome of the taxotere and cisplatin chemora- diotherapy to the advanced cervical cancer. Methods： Fifty-six cases with cervical cancer （FIGO lib to IVa） were divided randomly into two groups in the oncology hospital of Jingzhou from September 2009 to October 2010, radiotherapy alone （28 cases） and radiation plus chemotherapy （TP） group. There was no difference of radiotherapy between the two groups, the RT ＋ C cases who accepted TP regimen during the radiation, and DDP once weekly injection of vain, according to 20 mg/m2 and taxotere once weekly i.v. according to 35 mg/m2. These regimen were given for 4-5 weeks, and some medicine for vomit- ing was given to the RT ＋ C cases. Two groups were received an oral medicine MA 160 mg every day during the treatment. Results： The early outcome： the complete remission rate was 64.3% and partial remission rate was 35.7% in RT ＋ C. The complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remis- sion of RT ＋ C group was higher than that of the RT group. There was significant difference between the two groups. In RT ＋ C group, 1-year survive rate was 100.00% （28/28）; in RT group, 1-year survive rate was 85.71% （24/28）. There was significant difference between the two groups （X2 = 4.31 〉 3.84, P 〈 0.05）. Conclusion： The taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effect are raised, but that can be endured.展开更多
文摘目的了解医院产房自将乙肝疫苗(Hepatitis B Vaccine,HepB)纳入免疫规划后新生儿首针乙肝疫苗的接种情况及探讨其影响因素,为新生儿首针乙肝疫苗预防接种提供科学依据。方法采取回顾性调查分析方法,对2006～2009年鹿寨县所有医院产房出生新生儿首针乙肝疫苗接种情况进行调查分析。结果医院产房新生儿首针乙肝疫苗的接种率99.96%,及时接种率93.84%,影响未及时接种的因素以"早产、低体重、新生儿窒息、胎儿窘迫、新生儿疾病"为主,非疾病因素以"产程延长、胎膜早破、过期妊娠、羊水过少、婴儿吐奶、监护人拒接种等"为主。结论医务人员严格履行告知义务和提高新生儿疾病筛查、诊治力度,有利于及时接种首针乙肝疫苗。
文摘Objective： The aim of our study was to investigate the early outcome of the taxotere and cisplatin chemora- diotherapy to the advanced cervical cancer. Methods： Fifty-six cases with cervical cancer （FIGO lib to IVa） were divided randomly into two groups in the oncology hospital of Jingzhou from September 2009 to October 2010, radiotherapy alone （28 cases） and radiation plus chemotherapy （TP） group. There was no difference of radiotherapy between the two groups, the RT ＋ C cases who accepted TP regimen during the radiation, and DDP once weekly injection of vain, according to 20 mg/m2 and taxotere once weekly i.v. according to 35 mg/m2. These regimen were given for 4-5 weeks, and some medicine for vomit- ing was given to the RT ＋ C cases. Two groups were received an oral medicine MA 160 mg every day during the treatment. Results： The early outcome： the complete remission rate was 64.3% and partial remission rate was 35.7% in RT ＋ C. The complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remis- sion of RT ＋ C group was higher than that of the RT group. There was significant difference between the two groups. In RT ＋ C group, 1-year survive rate was 100.00% （28/28）; in RT group, 1-year survive rate was 85.71% （24/28）. There was significant difference between the two groups （X2 = 4.31 〉 3.84, P 〈 0.05）. Conclusion： The taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effect are raised, but that can be endured.
